Outcome | Ferritin level | No MAS | MAS |
|---|
 < 500 | 500–999 | 1000–2999 | 3000–9999 |  ≥ 10,000 |
|---|
No. of patients, N (%) | 280 (71) | 52 (13) | 30 (8) | 20 (5) | 15 (4) | 363 (91) | 34 (9) |
Lymphopenia, N (%)*** | 140 (50)c | 25 (48) | 5 (17) | 5 (25) | 4 (27) | 162 (45) | 17 (50) |
MechVent, N (%)** | 252 (90)c | 42 (81) | 20 (67) | 18 (90) | 10 (67) | 311 (86) | 31 (91) |
ECMO, N (%)*** | 8 (3) | 4 (8) | 1 (3) | 0 (0) | 2 (13) | 9 (3) | 6 (18)*** |
CRRT, N (%)*** | 5 (2) | 5 (10)a | 4 (13) | 1 (5)a | 1 (7)a | 10 (3) | 6 (18)*** |
PLEX, N (%)*** | 1 (0.3) | 1 (2) | 1 (3) | 0 (0) | 2 (13)a | 2 (0.6) | 3 (9)** |
Mortality, N (%)*** | 16 (6) | 8 (15) | 6 (20)a | 5 (25)a | 8 (53)a,b | 30 (8) | 13 (38)*** |
IPMOF, N (%)*** | 41 (15) | 16 (31) | 8 (27) | 10 (50)a | 9 (60)a | 64 (18) | 20 (59)*** |
TAMOF, N (%)*** | 12 (4) | 9 (17)a | 5 (17) | 4 (20)a | 7 (47)a | 16 (4) | 21 (62)*** |
MAS, N (%)*** | 10 (4) | 9 (17)a | 5 (17) | 2 (10) | 8 (53)a | – | – |
- Lymphopenia = Absolute Lymphocyte Count < 1,000/mm3
- Comparisons were performed between the group with ferritin < 500 and ferritin ≥ 500, and the group with MAS and without MAS. Kruskal–Wallis test was used for continuous variables, and the χ2 test or the Fisher’s exact test (group sample size < 10) was used for discrete variables. ***: P-value < 0.001 **: P-value < 0.01 *: P-value < 0.05
- IQR interquartile range, MechVent Mechanical Ventilation, ECMO Extracorporeal Membrane Oxygenation, CRRT Continuous Renal Replacement Therapies, PLEX Plasma Exchange, IPMOF immunoparalysis-associated multiple organ failure, TAMOF thrombocytopenia-associated multiple organ failure, MAS macrophage activation syndrome
- aThe outcome characteristic is significantly higher than ferritin < 500 group (P-value < 0.05)
- bThe outcome characteristic is significantly higher than ferritin 500–999 group (P-value < 0.05)
- cThe outcome characteristic is significantly higher than ferritin 1000–2999 group (P-value < 0.05)
